Does Blue Cross Blue Shield of Texas Cover Farxiga?

How BCBSTX Classifies Farxiga on Its Formulary

Blue Cross Blue Shield of Texas maintains multiple formulary lists that vary by plan type: commercial HMO, PPO, Medicare Advantage, and marketplace (ACA) plans. On most commercial formularies, Farxiga appears as a Tier 3 preferred brand-name medication. That classification means the drug is covered but carries a higher copay than generic alternatives like metformin (Tier 1) or brand-preferred agents with lower negotiated rates.

Commercial Plan Tiers

BCBSTX commercial plans generally use a four- or five-tier structure. Tier 1 holds generics, Tier 2 holds preferred brands, Tier 3 holds non-preferred brands, and Tiers 4 and 5 cover specialty medications. Farxiga lands on Tier 2 or Tier 3 depending on your specific employer-sponsored or individual plan. Employer groups that negotiate custom formularies may place it differently.

Medicare Advantage Placement

For BCBSTX Medicare Advantage (Part D) enrollees, Farxiga typically appears on Tier 3 as well. Under the Inflation Reduction Act provisions that took effect in 2025, Medicare Part D out-of-pocket costs are capped at $2,000 per year, which benefits patients taking brand-name SGLT2 inhibitors 1. The monthly cost during the initial coverage phase usually falls between $42 and $95 for a 30-day supply, though the annual cap means total exposure is limited.

Marketplace (ACA) Plans

ACA marketplace plans sold by BCBSTX in Texas must cover at least one SGLT2 inhibitor per essential health benefit requirements. Farxiga is the most commonly included SGLT2 option on these formularies, though some silver- and bronze-tier plans apply higher cost-sharing.

Prior Authorization and Step-Therapy Requirements

Most BCBSTX plans require prior authorization (PA) before dispensing Farxiga. Your prescribing physician must document that the drug is medically necessary and that certain clinical criteria are met.

What the PA Criteria Typically Include

BCBSTX formulary policies generally require documentation of a diagnosis of type 2 diabetes, heart failure, or chronic kidney disease (the three FDA-approved indications). For type 2 diabetes specifically, many plans also apply step therapy: the prescriber must show that the patient tried metformin first or has a documented contraindication to metformin, such as an estimated GFR below 30 mL/min/1.73 m² or a history of lactic acidosis 2.

Heart Failure and CKD Exceptions

Patients prescribed Farxiga specifically for heart failure or chronic kidney disease may qualify for an expedited PA pathway. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo in patients with HFrEF (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) 3. Following that landmark result, many payers, BCBSTX included, relaxed step-therapy requirements for the heart failure indication.

The DAPA-CKD trial (N=4,304) showed a 39% relative risk reduction in the composite of sustained decline in eGFR of 50% or greater, end-stage kidney disease, or renal or cardiovascular death (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) 4. That trial included patients both with and without diabetes, and the FDA broadened dapagliflozin's CKD indication accordingly in April 2021 5.

How Long PA Approval Takes

Standard PA decisions from BCBSTX are returned within 72 hours for non-urgent requests and within 24 hours for urgent requests. If your PA is denied, your physician can file a peer-to-peer appeal, which adds 5 to 10 business days. Denials are most often overturned when the prescriber submits documentation of a prior metformin trial or a valid contraindication.

What You Will Actually Pay Out of Pocket

The gap between list price and what you pay matters enormously. Farxiga's wholesale acquisition cost (WAC) sits around $580 for a 30-day supply, but almost no insured patient pays that amount.

Copay Ranges by Plan Type

For BCBSTX commercial PPO members, the most common copay range is $35 to $75 per 30-day fill when Farxiga sits on Tier 3. HMO plans with narrower networks sometimes negotiate better rates, and copays may drop to $30 to $50. High-deductible health plans (HDHPs) paired with a health savings account (HSA) require the patient to pay the full negotiated rate until the deductible is met. That negotiated rate typically runs $350 to $450 per fill before deductible satisfaction.

The AstraZeneca Copay Card

AstraZeneca offers a manufacturer copay assistance program for commercially insured patients. Eligible patients can pay as little as $0 per monthly fill, with a maximum annual benefit of $1,800 6. The card cannot be used with Medicare, Medicaid, TRICARE, or other federal programs. Patients enrolled in BCBSTX employer-sponsored or individual commercial plans generally qualify.

Pharmacy Choice and Cost Variation

Using a BCBSTX preferred pharmacy (CVS, Walgreens, or H-E-B Pharmacy, depending on your network) versus a non-preferred pharmacy can change your copay by $10 to $25 per fill. Mail-order through BCBSTX's pharmacy benefit manager often provides a 90-day supply for the cost of two copays, saving roughly 33% over three monthly fills.

Clinical Evidence Supporting Farxiga Coverage

Payers justify coverage decisions based on clinical trial data and guideline recommendations. Farxiga has one of the broadest evidence bases in the SGLT2 inhibitor class.

Type 2 Diabetes Efficacy

In a 24-week phase III trial, dapagliflozin 10 mg reduced HbA1c by 0.82% from baseline versus 0.30% with placebo (P<0.001), with a secondary benefit of 2.08 kg mean weight loss 7. The American Diabetes Association (ADA) 2025 Standards of Care list SGLT2 inhibitors as a preferred second-line agent after metformin for patients with established atherosclerotic cardiovascular disease, heart failure, or CKD 8.

Heart Failure Data

The DELIVER trial (N=6,263) extended dapagliflozin's heart failure evidence to patients with HFpEF (ejection fraction above 40%). The drug reduced the primary composite endpoint by 18% (HR 0.82; 95% CI 0.73 to 0.92; P<0.001) 9. Dr. Scott Solomon, principal investigator, stated: "These results confirm that dapagliflozin benefits patients with heart failure across the full spectrum of ejection fraction, a finding that changes how we approach treatment for millions of patients worldwide."

Kidney Protection Evidence

The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guideline recommends SGLT2 inhibitors for all patients with CKD and an eGFR of 20 to 45 mL/min/1.73 m², regardless of diabetes status 10. That recommendation drew heavily from DAPA-CKD, where the number needed to treat (NNT) to prevent one primary endpoint event over 2.4 years was just 19.

Cardiovascular Safety

The DECLARE-TIMI 58 trial (N=17,160) confirmed cardiovascular safety of dapagliflozin in a broad type 2 diabetes population, with a 17% reduction in cardiovascular death or hospitalization for heart failure (HR 0.83; 95% CI 0.73 to 0.95; P=0.005) 11. The study enrolled patients across 33 countries over a median follow-up of 4.2 years. That safety profile is one reason payers, including BCBSTX, grant formulary access rather than restricting the drug to specialty-only tiers.

How to Get Farxiga Covered if Your Plan Denies It

A denial does not mean the end of the road. Several appeal and alternative pathways exist within the BCBSTX system.

Filing a Formulary Exception

BCBSTX allows members to request a formulary exception if their physician documents medical necessity. The exception request must include the patient's diagnosis, prior medication trials, and a letter of medical necessity explaining why Farxiga is the appropriate therapy. Exception approvals typically move the drug to a lower cost-sharing tier or waive the PA requirement for a 12-month period.

External Review Rights in Texas

Texas Insurance Code Chapter 4201 gives patients the right to an independent external review if an internal appeal is denied 12. The Texas Department of Insurance assigns the case to an independent review organization (IRO). IRO decisions are binding on the insurer. For SGLT2 inhibitors with strong guideline support, IRO overturn rates exceed 60% when adequate clinical documentation is provided.

Switching Within the SGLT2 Class

If Farxiga specifically is non-preferred on your BCBSTX plan, ask your physician whether empagliflozin (Jardiance) occupies a preferred position. Both drugs belong to the same SGLT2 inhibitor class and share similar cardiovascular and renal benefits, though their trial populations differ. A meta-analysis of 10 SGLT2 inhibitor trials (N=71,553) found no statistically significant difference in cardiovascular mortality between dapagliflozin and empagliflozin (P=0.41) 13.

Farxiga Versus Other SGLT2 Inhibitors on BCBSTX

Formulary position determines cost more than clinical superiority does. Here is how the three major SGLT2 inhibitors typically compare on BCBSTX commercial formularies.

Empagliflozin (Jardiance)

Jardiance often shares the same tier as Farxiga on BCBSTX plans. Both carry PA requirements for the diabetes indication. Jardiance gained its heart failure indication based on the EMPEROR-Reduced (N=3,730) and EMPEROR-Preserved (N=5,988) trials 14. When both drugs sit on Tier 3, copays are comparable. The deciding factor is often which manufacturer copay card provides better savings.

Canagliflozin (Invokana)

Invokana is sometimes placed on a higher tier or removed from BCBSTX formularies entirely due to its FDA boxed warning history regarding lower-limb amputation risk (since removed but still influencing payer decisions). Patients currently on Invokana who switch to BCBSTX may need to transition to Farxiga or Jardiance.

Ertugliflozin (Steglatro)

Steglatro is less commonly covered. Merck discontinued its cardiovascular outcomes program for ertugliflozin, and the VERTIS-CV trial (N=8,246) did not demonstrate superiority over placebo for the primary MACE endpoint (HR 0.97; 95% CI 0.85 to 1.11; P=0.67) 15. That weaker evidence base has led many payers, including BCBSTX, to deprioritize ertugliflozin.

Side Effects That May Affect Coverage Decisions

Insurers track adverse event profiles when making formulary placement decisions. The most clinically relevant side effects of dapagliflozin include genital mycotic infections (occurring in 5% to 7% of female patients and 3% to 4% of male patients), urinary tract infections, volume depletion, and rare cases of diabetic ketoacidosis (DKA) 16.

Genital Infections

The elevated infection rate stems from glycosuria, the mechanism by which SGLT2 inhibitors lower blood glucose. BCBSTX does not restrict coverage based on infection risk, but patients with recurrent vulvovaginal candidiasis may have difficulty obtaining PA renewal.

DKA Risk

The FDA issued a Drug Safety Communication in 2015 and updated it in 2020 regarding SGLT2 inhibitor-associated DKA, which can present with near-normal blood glucose (euglycemic DKA) 17. Patients on insulin who are adding Farxiga should have insulin doses adjusted. BCBSTX PA criteria sometimes require documentation that the patient has been counseled on DKA warning signs.

Steps to Verify Your Specific BCBSTX Coverage

Coverage varies not just by plan type but by employer group and enrollment year. Take these concrete steps.

Contact BCBSTX member services at the number on the back of your insurance card and ask three specific questions: (1) Is dapagliflozin (Farxiga) on my formulary? (2) What tier is it on, and what is my copay? (3) Does my plan require prior authorization or step therapy? You can also log in to the BCBSTX member portal at bcbstx.com, manage to "Find a Drug," and search for dapagliflozin by name. The portal displays tier placement, PA requirements, and quantity limits for your specific plan.

Your prescribing physician's office can run a real-time benefit check (RTBC) through their electronic health record system. RTBC queries return patient-specific copay estimates and PA requirements before the prescription is even sent to the pharmacy, eliminating guesswork.